Type 2 diabetic nephropathy
Conditions
Interventions
control group:Irbesartan tablets (Oral, 2 tablets 75mg per tablet, once per day)
treatment group :Constant Gliflozin tablets (Oral, 1 tablet/time, 10mg per tablet, once/day)
Sponsors
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Patients who meet the diagnostic criteria for microalbuminuria phase of type 2 diabetic nephropathy; (2) Aged 18 to 70 years old (including 18 and 70), gender is not limited; (3)7.0% <= HbA1c <= 11%; (4) The subject was informed and voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with type 1 diabetes mellitus, gestational diabetes mellitus and other special types of diabetes mellitus; (2) Kidney damage caused by non-diabetic nephropathy; (3) Blood pressure >=160 / 100mmHg; (4) Patients with acute complications of diabetes mellitus; (5) Severe cardiac and cerebrovascular diseases and serious primary diseases, such as liver, kidney and hematopoietic system; (6) People with known allergies and allergic constitution to the study drug; (7) Pregnant and lactating women and women with recent family planning; (8) Long-term alcoholism, drug dependence, and patients with mental illness; (9) Those who have participated in or are participating in other drug clinical trials within one month before the screening period of the study; (10) The glomerular filtration rate is <45 ml min^(-1)*(1.73 m²)^(-1); (11) The investigator is not inappropriate to attend the clinical investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary albumin / creatinine; | — |
Secondary
| Measure | Time frame |
|---|---|
| fasting blood-glucose;glycosylated hemoglobin ;Blood glucose was obtained 2h after meal;G. F. R. ; | — |
Countries
China
Contacts
Public ContactZhao Jindong
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Outcome results
None listed